Cover Image
市場調查報告書

用子宮頸癌症診斷藥、治療藥的全球市場:診斷檢驗、手法、終端用戶、治療方法、各地區的詳細趨勢 (2014∼2020年)

Global Cervical Cancer Diagnostics and Therapeutics Market- Segmented by Diagnostic Test, Method, End-Users, Therapy, and Geography (2016-2021)

出版商 Mordor Intelligence LLP 商品編碼 353906
出版日期 內容資訊 英文 205 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
用子宮頸癌症診斷藥、治療藥的全球市場:診斷檢驗、手法、終端用戶、治療方法、各地區的詳細趨勢 (2014∼2020年) Global Cervical Cancer Diagnostics and Therapeutics Market- Segmented by Diagnostic Test, Method, End-Users, Therapy, and Geography (2016-2021)
出版日期: 2016年10月12日 內容資訊: 英文 205 Pages
簡介

全球子宮頸癌症相關市場 (診斷藥、治療藥等) ,2015年達到21億4000萬美元的規模,再加上2015∼2020年2∼5%的年複合成長率 (CAGR) 預計成長。根據世界衛生組織 (WHO) ,以開發中國家為中心,全球每年有27萬人女性因子宮頸癌症死亡。近幾年子宮頸抹片檢驗 (子宮頸細胞診斷檢驗) 和人類乳突病毒 (HPV) 檢驗,大腸內視鏡檢驗等早期診斷手法廣泛普及,使市場競爭變活躍同時,市場成長率也變高。在各地區中,北美各國約佔49%的市場佔有率。

本報告提供全球子宮頸癌症診斷藥、治療藥的市場相關分析,疾病概要和市場基本結構,主要的促進、阻礙因素,市場誘因、競爭力,整體市場及檢查項目別、各診斷手法、各終端用戶 (醫院,診療所,檢驗所等)、各地區的趨勢預測,市場競爭狀況,主要企業簡介等調查評估。

第1章 簡介

第2章 摘要整理

第3章 市場概要

  • 市場定義
  • 推動市場要素
    • 直腸結腸癌症的篩檢檢驗用開發中產品的增加
    • 人口高齡化
    • 在一般社會的認知度上升
  • 阻礙市場要素
    • 篩檢檢驗的費用
    • 諮詢
  • 市場機會

第4章 波特的五力分析

  • 供應商談判力
  • 買主談判力
  • 企業間競爭的程度
  • 替代產品的威脅
  • 新加入廠商的威脅

第5章 市場明細

  • 各診斷方法
    • 數位式直腸婦科檢查
    • 大便潛血試驗
    • 軟性S書結腸鏡子檢驗
    • 大腸內視鏡檢驗
    • 虛擬大腸鏡檢查內視鏡檢驗
  • 各治療手法
    • 外科手術、放射治療
    • 化療
    • 標靶治療
    • 對藥物療法的抗性
  • 各地區 (北美,歐洲,亞太地區,中東、非洲等)

第6章 競爭環境

  • 企業合併、收購 (M&A)
  • 契約、產業聯盟、產業合作
  • 新產品的銷售
  • 對新加入企業的建議

第7章 企業簡介

  • Abbott Diagnostics
  • Alere
  • Beckman Coulter
  • Clinical Genomics
  • Companion Dx
  • EDP Biotech
  • Epigenomics AG
  • Exact Sciences
  • FUJIREBIO (Miraca Holdings)
  • Genomic Tree
  • Metabiomics
  • Oncocyte (Biotime)
  • Quest Diagnostics
  • Randox Laboratories
  • Siemens Healthcare
  • Volition Rx

第8章 附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄

The global cervical cancer market was valued at USD 2,140 million in 2015 and is expected to grow at a CAGR of 2-5% during the period from 2015 to 2020.

Cervical cancer is generally characterized by the abnormal growth of cancerous cells in the tissues of the cervix, and it may manifest itself as a squamous-cell carcinoma or adenocarcinoma. According to the World Health Organization (WHO), cervical cancer accounts for the death of more than 270,000 women annually, primarily in the developing countries. With the increasing use of cervical cancer diagnostic tests such as pap smear tests, HPV testing, and colposcopy for early detection, the market is highly competitive with a high growth rate.

Global Cervical Cancer Diagnostics and Therapeutics Market-Market Dynamics

The advent of technologically advanced computer-guided screening tests for cervical cancer in order to reduce the rate of false-negative results and improved accuracy are expected to contribute to the growth of the cervical cancer diagnostic tests market during the forecast period, from 2014 to 2020.

Drivers

Some factors contributing to the growth of the market are:

  • Rising prevalence of cervical cancer
  • Favorable government initiatives
  • Funding to increase disease awareness
  • Increase of pipeline cervical cancer screening tests
  • Aging population
  • Increasing consumer awareness

Restraints

Some factors limiting the growth of the market are:

  • Cost of screening tests
  • Availability of HPV vaccines
  • Uncertain reimbursement rates
  • Changes in regulatory guidelines

The global cervical cancer diagnostic and therapeutic market is segmented on the basis of diagnostics test (Pap smear test, HPV testing, colposcopy, cervical cancer biopsy), methods (molecular method, cytopathological method, physical method), end-users (hospitals, laboratories, independent physicians, clinics, and others), therapies (surgery, radiation therapy, chemotherapy and others) and geography (North America, Asia-Pacific, Europe, Middle East & Africa and Latin America). North America is expected to account for almost 49% of the total market share by 2020.

Some of the key players in the market are:

  • Abbott Diagnostics
  • Becton Deckinson and Company
  • Roche
  • Qiagen
  • Siemens Healthcare

What the Report Offers

  • Market definition along with identification of key drivers and restraints for the market.
  • Market analysis with region-specific assessments and competition analysis on a global and regional scale.
  • Identification of factors instrumental in changing the market scenario, rising prospective opportunities and identification of key companies that can influence the market on a global and regional scale.
  • Extensively researched competitive landscape section with profiles of major companies along with their strategic initiatives and market share.
  • Identification and analysis of the macro and micro factors that affect the industry on both a global and regional scale.
  • A comprehensive list of key market players along with the analysis of their current strategic interests and key financial information.
  • An ideal source material for industry consultants, manufacturers and other interested and allied parties to gain a critical insight into the factors driving and restraining the market, in addition to opportunities offered.

Table of Contents

1. Introduction

  • 1.1. Study Deliverables
  • 1.2. Market Definition
  • 1.3. Sizing Units
  • 1.4. Base Currency
  • 1.5. Review and Forecast Period Years
  • 1.6. General Study Assumptions

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Analysis Methodology
  • 2.3. Econometric Forecast Model
  • 2.4. Research Assumptions

3. Executive Summary

4. Key Inferences

5. Market Overview and Industry Trends

  • 5.1. Current Market Scenario
  • 5.2. Applications of Cervical Cancer diagnostics and therapeutics
  • 5.3. Technology Overview
  • 5.4. New Developments
  • 5.5. Industry Value-Chain Analysis
  • 5.6. Product Life-Cycle Analysis
  • 5.7. Product Benchmarking
  • 5.8. Investment Analysis
  • 5.8. Portera€™s Five Forces
    • 5.8.1. Bargaining Power of Suppliers
    • 5.8.2. Bargaining Power of Consumers
    • 5.8.3. Threat of New Entrants
    • 5.8.4. Threat of Substitute Products and Services
    • 5.8.5. Competitive Rivalry within the Industry

6. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)

  • 6.1. Market Drivers
    • 6.1.1. Increasing prevalence of cervical cancer
    • 6.1.2. Increasing incidences of weakened immune system
    • 6.1.3. High use of cervical cancer diagnostic tests
    • 6.1.4. Long-term use of oral contraceptive pills
    • 6.1.5. Rapid spread of human papillomavirus (HPV) infection
    • 6.1.6. Favorable government initiatives and funding
    • 6.1.7. Lifestyle-related factors
  • 6.2. Market Restraints
    • 6.2.1. High cost of cancer therapeutics
    • 6.2.2. Changes in regulatory guidelines for cervical cancer screening
    • 6.2.3. Use of HPV vaccines
    • 6.2.4. Uncertain reimbursement rates
  • 6.3. Key Challenges
  • 6.4. Current Opportunities in the Market

7. Market Segmentation

  • 7.1. By End-Users
    • 7.1.1. Hospitals
    • 7.1.2. Clinical laboratories
    • 7.1.3. Healthcare centers
  • 7.2. Diagnostic tests
    • 7.2.1. Pap smear test
    • 7.2.2. HPV testing
    • 7.2.3. Colposcopy
    • 7.2.4. Loop Electrosurgical Excision Procedure
    • 7.2.5. Biopsy
    • 7.2.6. Endocervical Curettage
  • 7.3. Screening methods
    • 7.3.1. Molecular method
    • 7.3.2. Cytopathological method
    • 7.3.3. Physical method
  • 7.4. Therapy
    • 7.4.1. Surgery
    • 7.4.2. Radiation therapy
    • 7.4.3. Chemotherapy
    • 7.4.4. Vaccines
  • 7.5. By Geography
    • 7.5.1. North America
      • 7.5.1.0. Introduction
      • 7.5.1.1. US
      • 7.5.1.2. Canada
      • 7.5.1.3. Rest of North America
    • 7.5.2. Europe
      • 7.5.2.0. Introduction
      • 7.5.2.1. France
      • 7.5.2.2. UK
      • 7.5.2.3. Germany
      • 7.5.2.4. Russia
      • 7.5.2.5. Italy
      • 7.5.2.6. Spain
      • 7.5.2.7. Rest of Europe
    • 7.5.3. Asia-Pacific
      • 7.5.3.0. Introduction
      • 7.5.3.1. India
      • 7.5.3.2. China
      • 7.5.3.3. Japan
      • 7.5.3.4. Australia
      • 7.5.3.5. South Korea
      • 7.5.3.6. Rest of Asia-Pacific
    • 7.5.4. Middle East and Africa (MEA)
      • 7.5.4.1. Introduction
      • 7.5.4.2. UAE
      • 7.5.4.3. Saudi Arabia
      • 7.5.4.4. Israel
      • 7.5.4.5. Rest of the MEA
    • 7.5.5. Latin America
      • 7.5.5.1. Introduction
      • 7.5.5.2. Brazil
      • 7.5.5.1. Argentina
      • 7.5.5.4. Mexico
      • 7.5.5.5. Rest of Latin America

8. Competitive Landscape

  • 8.1. Merger and Acquisition Analysis
  • 8.2. Patent Analysis
  • 8.3. The Challengers

9. Company Profiles

  • 9.1. Abbott Diagnostics
  • 9.2. Becton Deckinson and Company
  • 9.3. Roche
  • 9.4. Qiagen
  • 9.5. Siemens Healthcare
  • 9.6. Dendreon Corporation
  • 9.7. Otsuka Pharmaceuticals
  • 9.8. Merck
  • 9.9. GlaxoSmithKline PLC
  • 9.10. Advaxis Immunotherapies
  • 9.11. Bionor Pharma

10. Analyst Outlook for Investment Opportunities

11. Future Outlook of the Market

Back to Top